PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 48 filers reported holding PROQR THRAPEUTICS N V in Q4 2020. The put-call ratio across all filers is 13.85 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $325 | -99.9% | 200,499 | -66.0% | 0.00% | -100.0% |
| Q3 2022 | $439,000 | -39.2% | 590,568 | -36.4% | 0.00% | 0.0% |
| Q2 2022 | $722,000 | +32.0% | 929,000 | +53.8% | 0.00% | 0.0% |
| Q1 2022 | $547,000 | -61.2% | 604,181 | +80.2% | 0.00% | -50.0% |
| Q4 2020 | $1,408,000 | +108.6% | 335,300 | +137.8% | 0.00% | +100.0% |
| Q3 2020 | $675,000 | -23.8% | 141,000 | -3.2% | 0.00% | 0.0% |
| Q2 2020 | $886,000 | +336.5% | 145,700 | +293.8% | 0.00% | – |
| Q1 2020 | $203,000 | -75.3% | 37,000 | -55.4% | 0.00% | -100.0% |
| Q4 2019 | $823,000 | +39.7% | 83,000 | -18.9% | 0.00% | – |
| Q3 2019 | $589,000 | +263.6% | 102,300 | +474.7% | 0.00% | – |
| Q2 2019 | $162,000 | -23.6% | 17,800 | +16.3% | 0.00% | – |
| Q1 2019 | $212,000 | +236.5% | 15,300 | +17.7% | 0.00% | – |
| Q2 2016 | $63,000 | -74.3% | 13,000 | -11.5% | 0.00% | -100.0% |
| Q2 2015 | $245,000 | – | 14,697 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 1,237,400 | $5,197,000 | 1.55% |
| Prosight Management, LP | 255,000 | $1,071,000 | 0.50% |
| RTW INVESTMENTS, LP | 5,009,768 | $21,041,000 | 0.35% |
| Kerrisdale Advisers, LLC | 453,182 | $1,903,000 | 0.15% |
| Artal Group S.A. | 1,196,218 | $5,024,000 | 0.11% |
| COWEN AND COMPANY, LLC | 285,696 | $1,200,000 | 0.11% |
| Golden Green, Inc. | 16,999 | $71,000 | 0.07% |
| APOGEM CAPITAL LLC | 15,855 | $67,000 | 0.04% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4,550,062 | $19,110,000 | 0.04% |
| ALTRINSIC GLOBAL ADVISORS LLC | 241,360 | $1,014,000 | 0.03% |